Expansion opportunities Niowave is actively expanding in Michigan with multiple large-scale projects including a $75M radiopharmaceutical isotope facility and a $65M airport-based expansion, signaling a growing domestic Ac-225 supply chain and potential capacity-related sales for supporting construction, equipment, and ongoing operations.

Strategic partnerships A 50/50 collaboration with Aptevo Therapeutics to develop radiopharmaceutical oncology programs creates joint development opportunities, co-marketing potential, and cross-sell trajectories for Niowave’s Ac-225 production capabilities and related radiochemistry services.

Long-term partnerships The 10-year supply agreement with AZ to produce Ac-225 indicates durable, high-value off-take commitments, suggesting sales opportunities in long-term licensing, contract manufacturing, and scalable isotope production capacity upgrades.

Technology differentiator Niowave’s use of superconducting linac for Ac-225 production avoids reactors and HEU licensing, offering a favorable compliance and operating profile that can be pitched to biotech and pharma partners seeking simpler, cost-effective radiopharmaceutical supply chains.

Domestic supply focus Ongoing investments to strengthen domestic Actinium-225 supply align with market trends toward regionalized, FDA-aligned radiopharmaceutical manufacturing, presenting sales angles for integrated supply, logistics efficiency, and regulatory-ready turnkey production solutions.